• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

After M&A stretch, Pfizer CEO says company needs 'breathing period' from large deals

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 11, 2024 at 11:42: AM
via Amid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes.

Though not for lack of business development capacity, Pfizer is currently taking a large dealmaking “breathing period,” CEO Albert Bourla told investors this week at Goldman Sachs’ 2024 annual Global Healthcare Conference in Miami.

article source
 




Top Bottom
Back
Quote